USA - engelsk - NLM (National Library of Medicine)

mckesson corporation dba rx pak - butalbital (unii: khs0az4jvk) (butalbital - unii:khs0az4jvk), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) - butalbital 50 mg - fioricet is indicated for the relief of the symptom complex of tension (or muscle contraction) headache. evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. caution in this regard is required because butalbital is habit-forming and potentially abusable. this product is contraindicated under the following conditions: - hypersensitivity or intolerance to any component of this product patients with porphyria. butalbital barbiturates may be habit-forming: tolerance, psychological dependence, and physical dependence may occur especially following prolonged use of high doses of barbiturates. the average daily dose for the barbiturate addict is usually about 1500 mg. as tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fatal dosage, however, does not increase more than two-fold. as this occurs, the margin between an intoxication dosage and fatal dosage become

USA - engelsk - NLM (National Library of Medicine)

mckesson corporation dba rx pak - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - methylphenidate hydrochloride 40 mg - metadate cd is contraindicated in patients with marked anxiety, tension and agitation, since the drug may aggravate these symptoms. metadate cd is contraindicated in patients known to be hypersensitive to methylphenidate or other components of the product. metadate cd contains sucrose. therefore, patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency should not take this medicine. metadate cd is contraindicated in patients with glaucoma. metadate cd is contraindicated in patients with motor tics or with a family history or diagnosis of tourette's syndrome (see adverse reactions). metadate cd is contraindicated during treatment with monoamine oxidase inhibitors, and also within a minimum of 14 days following discontinuation of a monoamine oxidase inhibitor (hypertensive crises may result). metadate cd is contraindicated in patients with severe hypertension, angina pectoris, cardiac arrhythmias, heart failure, recent myocardial infarc

USA - engelsk - NLM (National Library of Medicine)

mckesson corporation dba rx pak - lorazepam (unii: o26fzp769l) (lorazepam - unii:o26fzp769l) - lorazepam 0.5 mg - lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. the physician should periodically reassess the usefulness of the drug for the individual patient. lorazepam is contraindicated in patients with

USA - engelsk - NLM (National Library of Medicine)

mckesson corporation dba rx pak - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine is indicated in: - short term treatment of active duodenal ulcer. most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. controlled studies in adults have not extended beyond one year. - short term treatment of active benign gastric ulcer. most adult patients heal within 6 weeks. studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. - short term treatment of gastroesophageal reflux disease (gerd). famotidine is indicated for short term treatment of patients with symptoms of gerd (see clinical pharmacology in adults, clinical studies ). famotidine is also i

USA - engelsk - NLM (National Library of Medicine)

mckesson corporation dba rx pak - pravastatin sodium (unii: 3m8608uq61) (pravastatin - unii:kxo2kt9n0g) - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in hypercholesterolemic patients without clinically evident coronary heart disease (chd), pravastatin sodium tablet, usp is indicated to: -   reduce the risk of myocardial infarction (mi). -   reduce the risk of undergoing myocardial revascularization procedures. -   reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. in patients with clinically evident chd, pravastatin sodium tablet is indicated to: -   reduce the risk of total mortality by reducing coronary death. -   reduce the risk of mi. -   reduce the risk of undergoing myocardial revascularization procedures. -  

USA - engelsk - NLM (National Library of Medicine)

mckesson corporation dba rx pak - tamoxifen citrate (unii: 7frv7310n6) (tamoxifen - unii:094zi81y45) - tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. in premenopausal women with metastatic breast cancer, tamoxifen is an alternative to oophorectomy or ovarian irradiation. available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen therapy. tamoxifen citrate tablets are indicated for the treatment of node-positive breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. in some tamoxifen adjuvant studies, most of the benefit to date has been in the subgroup with four or more positive axillary nodes. tamoxifen citrate tablets are indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. the estrogen and progesterone receptor values may help to predict whether adjuvant tamoxifen therapy is likely to be beneficial. t

USA - engelsk - NLM (National Library of Medicine)

mckesson corporation dba rx pak - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa and levodopa tablets, usp are indicated in the treatment of parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. carbidopa allows patients treated for parkinson's disease to use much lower doses of levodopa. some patients who responded poorly to levodopa have improved on carbidopa and levodopa. this is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. carbidopa may also reduce nausea and vomiting and permit more rapid titration of levodopa. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa. these inhibitors must be discontinued at least two weeks prior to initiating therapy with this combination product. carbidopa and levodopa may be administered conc

USA - engelsk - NLM (National Library of Medicine)

mckesson corporation dba rx pak - hydralazine hydrochloride (unii: fd171b778y) (hydralazine - unii:26nak24ls8) - essential hypertension, alone or as an adjunct. hypersensitivity to hydralazine; coronary artery disease; mitral valvular rheumatic heart disease.

USA - engelsk - NLM (National Library of Medicine)

mckesson corporation dba rx pak - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - - sedative - anticonvulsant – for the treatment of generalized and partial seizures. phenobarbital is contraindicated in patients who are hypersensitive to barbiturates, in patients with a history of manifest or latent porphyria, and in patients with marked impairment of liver function or respiratory disease in which dyspnea or obstruction is evident. phenobarbital is a schedule iv drug. barbiturates may be habit forming. tolerance, psychological dependence, and physical dependence may occur, especially following prolonged use of high doses of barbiturates. daily administration in excess of 400 mg of pentobarbital or secobarbital for approximately 90 days is likely to produce some degree of physical dependence. a dosage of 600 to 800 mg taken for at least 35 days is sufficient to produce withdrawal seizures. the average daily dose for the barbiturate addict is usually about 1.5 g. as tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fata

USA - engelsk - NLM (National Library of Medicine)

mckesson corporation dba rx pak - ondansetron hydrochloride (unii: nmh84ozk2b) (ondansetron - unii:4af302esos) - ondansetron tablets are indicated for the prevention of nausea and vomiting associated with: - highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m2 . - initial and repeat courses of moderately emetogenic cancer chemotherapy. - radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. ondansetron tablets are also indicated for the prevention of postoperative nausea and/or vomiting. ondansetron tablets are contraindicated in patients: - known to have hypersensitivity (e.g., anaphylaxis) to ondansetron or any of the components of the formulation [see adverse reactions (6.2)]. - receiving concomitant apomorphine due to the risk of profound hypotension and loss of consciousness. risk summary   available data do not reliably inform the association of ondansetron tablets and adverse fetal outcomes. published epidemiological studies on the association between ondansetron and fetal outcomes